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A commentary on
The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons
cultured from adult P301S tau mice
by Brelstaff, J., Ossola, B., Neher, J. J., Klingstedt, T., Nilsson, K. P. R., Goedert, M., et al. (2015). Front.
Neurosci. 9:184. doi: 10.3389/fnins.2015.00184
Biomedical research directed to understand the pathophysiology of Alzheimer’s disease (AD) has
contributed to the characterization of two pathological hallmarks of this terrible disease, namely
senile plaques and neurofibrillary tangles. Neuropathological studies indicated that the level of
accumulation of these pathological lesions correlate with the severity of the clinical presentation
(Braak and Braak, 1991; Hyman et al., 2012). Senile plaques are formed by the accumulation of
Aβ peptides derived from the proteolysis of the Amyloid Precursor Protein, while neurofibrillary
tangles are ultrastructures predominantly compose of aberrantly phosphorylated tau proteins.
Previous studies indicated that reduction of Aβ peptides and increase of phosphorylated tau
peptides in the cerebrospinal fluid (CSF) serve as biomarkers to confirm the diagnosis of probable
AD (Olsson et al., 2016). Despite the detected correlation, questions about the sensitivity of
the assay and temporal disconnect with the genesis of pathological tau in the brain, as well as
the invasive nature of a lumbar puncture, makes CSF analysis a rather unlikely approach for
mainstream clinical laboratory testing. Alternatively, serum and/or plasma are routinely used
for clinical diagnosis purposes. However, the specificity of putative biomarkers has not reach a
desirable level of certainty for the diagnosis of AD (Olsson et al., 2016). Therefore, due to the low
invasiveness and promising results already obtained, most research efforts have been re-directed
to develop selective molecules that facilitate the imaging of pathological proteins in living neurons
and individuals.
The knowledge gained from neuropathological studies of AD cases has been used as the basis to
direct the development ofmolecules that are able to specifically interact with Aβ or tau oligomers, in
brain regions of interest in living individuals. The selection of these brain regions of interest is based
on the hierarchical and sequential appearance of pathological lesions in postmortem tissue and its
correlation with functional impairments observed in living individuals (Braak and Braak, 1991;
Hyman et al., 2012). Although different studies showed that the detection of Aβ pathology precede
the detection of pathological tau, it is the accumulation of tau aggregates at specific brain regions
that directly correlates with executive dysfunction and cognitive impairment in AD (Arriagada
et al., 1992; Jack et al., 2013). Hence, different molecules have been developed in the quest to
selectively visualize and study the accumulation of pathological tau proteins.
Brelstaff et al. (2015) demonstrated that pentameric formyl thiophene acetic acid (pFTAA) is
able to bind filamentous tau proteins in living neurons. pFTAA is a fluorescence dye that selectively
binds to beta-sheets conformations characteristic of amyloid proteins, including Aβ oligomers
and fibrilar tau. In this study, pFTAA was injected intravenously via the tail vein of transgenic
mice overexpressing the human tau-P301S mutant gene (Brelstaff et al., 2015). The mice were
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euthanized after 48 h and the brain stained with antibodies
that are known to detected pathological tau (e.g., MC1,
AT100). The results showed that peripherally injected pFTAA
selectively labeled neurons that were positive for the presence
of pathological tau, demonstrating the blood brain barrier
permeability of pFTAA and its uptake by living neurons.
Consistently, pFTAA also label pathological tau formed in
cultured dorsal root ganglion neurons from htau-P301S
transgenic mice. They also demonstrated that pFTAA positive
neurons in culture had a shorter survival rate than pFTAA
negative neurons (Brelstaff et al., 2015). Thus, this study
demonstrated, for the first time, that pFTAA detects pathological
tau in living neurons, becoming a valuable tool to assess
compounds that target the aggregation and/or promote
the disaggregation of pathological tau in cultured neurons,
including iPSC-derived neurons from tauopathy patients.
Additionally, pFTAA labeling may facilitate the study of
molecular mechanisms that contribute to pathological tau
aggregation in cultured neurons. Although, this study represents
an important progress in the development of molecular tools
to study the formation and metabolism of aggregated tau,
we need to take in consideration the limitations of assessing
the formation of toxic forms of tau in cultured cells. In
addition, many important questions regarding tau-mediated
neurodegeneration remain unanswered.
The main question in AD and other tauopathies that remain
unanswered is the definition of pathological tau. For example,
pFTAA staining indicates that the presence of fibrillar tau is
associated with reduced survival of cultured neuron. However,
due to the temporal cell death process of pFTAA positive
cells, it is difficult to differentiate between the toxic effect that
early stages of tau oligomerization and later forms of fibrillar
tau could exert to the cell. In this regard, we should ask:
what specific aberrant tau structure is toxic to neurons? Is
there a temporal accumulation of different tau structures or
aggregate species that mediate distinct pathological signals? Are
neuropathological hallmarks (neurofibrillary tangles) a cause or
consequence of the pathophysiological process? Is the lack of
detectable tau aggregates enough evidence to determine that
a specific brain region is resilient to tauopathy or that the
brain is free of toxic tau? Perhaps, the temporal characterization
of different tau species using conformation-specific anti-tau
antibodies and labeling molecules, such as pFTAA or tau-specific
PET radiotracers (Shimojo et al., 2015), could provide insights
about the evolution of toxic tau.
Johnson et al. (2016) and Schöll et al. (2016) got closer, using
the positron emission tomography (PET) tau-ligand AV-1451, to
achieving the ultimate goal of performing brain imaging to track
the progression of tau pathology in living individuals. However,
the correlation of tau levels and cognitive decline suggests that
patients already experienced significant brain damage before
detection of pathological tau. Moreover, it is not clear if detection
of AV-1451 in “healthy aging brain” represents a pre-clinical
stage or a normal by-product of tau metabolism. Although the
optimization of molecules that selectively detect specific tau
pathological species will be extremely beneficial for diagnosis and
assessment of therapeutic interventions, research effort should
also be directed to understand molecular signals that could be
used to detect cellular stress before pathological aggregates are
detected. Therefore, further studies that contribute to define
the structural characteristics and temporal accumulation of
pathological tau species and the cellular response to these species
will contribute to the development of better diagnostic tools.
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